Literature DB >> 26552846

Pyk2 and Megakaryocytes Regulate Osteoblast Differentiation and Migration Via Distinct and Overlapping Mechanisms.

Pierre P Eleniste1, Vruti Patel1, Sumana Posritong1, Odette Zero1, Heather Largura1, Ying-Hua Cheng2, Evan R Himes2, Matthew Hamilton2, Jenna T B Ekwealor2, Melissa A Kacena2, Angela Bruzzaniti1.   

Abstract

Osteoblast differentiation and migration are necessary for bone formation during bone remodeling. Mice lacking the proline-rich tyrosine kinase Pyk2 (Pyk2-KO) have increased bone mass, in part due to increased osteoblast proliferation. Megakaryocytes (MKs), the platelet-producing cells, also promote osteoblast proliferation in vitro and bone-formation in vivo via a pathway that involves Pyk2. In the current study, we examined the mechanism of action of Pyk2, and the role of MKs, on osteoblast differentiation and migration. We found that Pyk2-KO osteoblasts express elevated alkaline phosphatase (ALP), type I collagen and osteocalcin mRNA levels as well as increased ALP activity, and mineralization, confirming that Pyk2 negatively regulates osteoblast function. Since Pyk2 Y402 phosphorylation is important for its catalytic activity and for its protein-scaffolding functions, we expressed the phosphorylation-mutant (Pyk2(Y402F) ) and kinase-mutant (Pyk2(K457A) ) in Pyk2-KO osteoblasts. Both Pyk2(Y402F) and Pyk2(K457A) reduced ALP activity, whereas only kinase-inactive Pyk2(K457A) inhibited Pyk2-KO osteoblast migration. Consistent with a role for Pyk2 on ALP activity, co-culture of MKs with osteoblasts led to a decrease in the level of phosphorylated Pyk2 (pY402) as well as a decrease in ALP activity. Although, Pyk2-KO osteoblasts exhibited increased migration compared to wild-type osteoblasts, Pyk2 expression was not required necessary for the ability of MKs to stimulate osteoblast migration. Together, these data suggest that osteoblast differentiation and migration are inversely regulated by MKs via distinct Pyk2-dependent and independent signaling pathways. Novel drugs that distinguish between the kinase-dependent or protein-scaffolding functions of Pyk2 may provide therapeutic specificity for the control of bone-related diseases.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  ALKALINE PHOSPHATASE; BONE FORMATION; MINERALIZATION; PHOSPHORYLATION; TYROSINE KINASE

Mesh:

Substances:

Year:  2015        PMID: 26552846      PMCID: PMC4821770          DOI: 10.1002/jcb.25430

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  46 in total

1.  RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation in a Src-independent manner.

Authors:  Shin-Young Park; Hava Karsenty Avraham; Shalom Avraham
Journal:  J Biol Chem       Date:  2004-05-27       Impact factor: 5.157

Review 2.  RAFTK/Pyk2-mediated cellular signalling.

Authors:  H Avraham; S Y Park; K Schinkmann; S Avraham
Journal:  Cell Signal       Date:  2000-03       Impact factor: 4.315

3.  Involvement of proline-rich tyrosine kinase 2 in platelet activation: tyrosine phosphorylation mostly dependent on alphaIIbbeta3 integrin and protein kinase C, translocation to the cytoskeleton and association with Shc through Grb2.

Authors:  T Ohmori; Y Yatomi; N Asazuma; K Satoh; Y Ozaki
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

4.  Inhibition of osteoclast function by adenovirus expressing antisense protein-tyrosine kinase 2.

Authors:  L T Duong; I Nakamura; P T Lakkakorpi; L Lipfert; A J Bett; G A Rodan
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

5.  High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.

Authors:  J L Villeval; K Cohen-Solal; M Tulliez; S Giraudier; J Guichard; S A Burstein; E M Cramer; W Vainchenker; F Wendling
Journal:  Blood       Date:  1997-12-01       Impact factor: 22.113

6.  Formation of bone by isolated, cultured osteoblasts in millipore diffusion chambers.

Authors:  D J Simmons; G N Kent; R L Jilka; D M Scott; M Fallon; D V Cohn
Journal:  Calcif Tissue Int       Date:  1982-05       Impact factor: 4.333

7.  Dynamin reduces Pyk2 Y402 phosphorylation and SRC binding in osteoclasts.

Authors:  Angela Bruzzaniti; Lynn Neff; Amanda Sandoval; Liping Du; William C Horne; Roland Baron
Journal:  Mol Cell Biol       Date:  2009-04-20       Impact factor: 4.272

8.  Cyclic strain promotes shuttling of PYK2/Hic-5 complex from focal contacts in osteoblast-like cells.

Authors:  Alain Guignandon; Nadia Boutahar; Aline Rattner; Laurence Vico; Marie-Hélène Lafage-Proust
Journal:  Biochem Biophys Res Commun       Date:  2006-03-09       Impact factor: 3.575

9.  The role of gap junctions in megakaryocyte-mediated osteoblast proliferation and differentiation.

Authors:  Wendy A Ciovacco; Carolyn G Goldberg; Amanda F Taylor; Justin M Lemieux; Mark C Horowitz; Henry J Donahue; Melissa A Kacena
Journal:  Bone       Date:  2008-09-10       Impact factor: 4.398

10.  Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design.

Authors:  Seungil Han; Anil Mistry; Jeanne S Chang; David Cunningham; Matt Griffor; Peter C Bonnette; Hong Wang; Boris A Chrunyk; Gary E Aspnes; Daniel P Walker; Arthur D Brosius; Leonard Buckbinder
Journal:  J Biol Chem       Date:  2009-02-25       Impact factor: 5.157

View more
  10 in total

1.  Lnk Deficiency Leads to TPO-Mediated Osteoclastogenesis and Increased Bone Mass Phenotype.

Authors:  David J Olivos; Marta Alvarez; Ying-Hua Cheng; Richard Adam Hooker; Wendy A Ciovacco; Monique Bethel; Haley McGough; Christopher Yim; Brahmananda R Chitteti; Pierre P Eleniste; Mark C Horowitz; Edward F Srour; Angela Bruzzaniti; Robyn K Fuchs; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2017-04-18       Impact factor: 4.429

2.  Aging negatively impacts the ability of megakaryocytes to stimulate osteoblast proliferation and bone mass.

Authors:  Kevin A Maupin; Evan R Himes; Artur P Plett; Hui Lin Chua; Pratibha Singh; Joydeep Ghosh; Safa F Mohamad; Irushi Abeysekera; Alexa Fisher; Carol Sampson; Jung-Min Hong; Paul Childress; Marta Alvarez; Edward F Srour; Angela Bruzzaniti; Louis M Pelus; Christie M Orschell; Melissa A Kacena
Journal:  Bone       Date:  2019-07-09       Impact factor: 4.398

3.  Pyk2 deficiency potentiates osteoblast differentiation and mineralizing activity in response to estrogen or raloxifene.

Authors:  Sumana Posritong; Jung Min Hong; Pierre P Eleniste; Patrick W McIntyre; Jennifer L Wu; Evan R Himes; Vruti Patel; Melissa A Kacena; Angela Bruzzaniti
Journal:  Mol Cell Endocrinol       Date:  2018-02-08       Impact factor: 4.102

4.  Focal adhesion kinase inhibitors prevent osteoblast mineralization in part due to suppression of Akt-mediated stabilization of osterix.

Authors:  Scott A Gunn; Lauren M Kreps; Huijun Zhao; Katelyn Landon; Jacob S Ilacqua; Christina L Addison
Journal:  J Bone Oncol       Date:  2022-05-13       Impact factor: 4.491

Review 5.  Cellular components of the hematopoietic niche and their regulation of hematopoietic stem cell function.

Authors:  Joydeep Ghosh; Roy El Koussa; Safa F Mohamad; Jianyun Liu; Melissa A Kacena; Edward F Srour
Journal:  Curr Opin Hematol       Date:  2021-07-01       Impact factor: 3.218

6.  ANK1 is up-regulated in laser captured microglia in Alzheimer's brain; the importance of addressing cellular heterogeneity.

Authors:  Diego Mastroeni; Shobana Sekar; Jennifer Nolz; Elaine Delvaux; Katie Lunnon; Jonathan Mill; Winnie S Liang; Paul D Coleman
Journal:  PLoS One       Date:  2017-07-12       Impact factor: 3.240

7.  Enhancement of osteoblast activity on nanostructured NiTi/hydroxyapatite coatings on additive manufactured NiTi metal implants by nanosecond pulsed laser sintering.

Authors:  Biwei Deng; Angela Bruzzaniti; Gary J Cheng
Journal:  Int J Nanomedicine       Date:  2018-11-30

8.  Megakaryocytes promote osteoclastogenesis in aging.

Authors:  Deepa Kanagasabapathy; Rachel J Blosser; Kevin A Maupin; Jung Min Hong; Marta Alvarez; Joydeep Ghosh; Safa F Mohamad; Alexandra Aguilar-Perez; Edward F Srour; Melissa A Kacena; Angela Bruzzaniti
Journal:  Aging (Albany NY)       Date:  2020-07-07       Impact factor: 5.682

9.  SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.

Authors:  Roy Heusschen; Joséphine Muller; Marilène Binsfeld; Caroline Marty; Erwan Plougonven; Sophie Dubois; Nadia Mahli; Karen Moermans; Geert Carmeliet; Angélique Léonard; Frédéric Baron; Yves Beguin; Eline Menu; Martine Cohen-Solal; Jo Caers
Journal:  Oncotarget       Date:  2016-05-24

10.  Flavonoid compound icariin enhances BMP-2 induced differentiation and signalling by targeting to connective tissue growth factor (CTGF) in SAMP6 osteoblasts.

Authors:  Bing Xu; Xueqiang Wang; Chengliang Wu; Lihe Zhu; Ou Chen; Xiaofeng Wang
Journal:  PLoS One       Date:  2018-07-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.